BioCentury
ARTICLE | Financial News

CStone lines up for Hong Kong IPO

November 12, 2018 11:43 PM UTC

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) on Monday proposed to list on the Hong Kong stock exchange in an IPO underwritten by Goldman Sachs and Morgan Stanley.

CStone’s management team includes Chairman and CEO Frank Ningjun Jiang, CMO Jianxin Yang and CFO Richard Yeh. Jiang was head of Asia-Pacific R&D at the Sanofi China unit of Sanofi (Euronext:SAN; NYSE:SNY); Yang served as SVP and head of clinical development at BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160); and Yeh was the managing director at Goldman Sachs in Hong Kong...